Literature DB >> 32203000

Dilatation Reserve of Pulmonary Arteries at Stages of the Chronic Obstructive Pulmonary Disease Model.

Nataliya A Kuzubova1, Elena S Lebedeva1, Olga N Titova1, Tatiana N Preobrazhenskaya2.   

Abstract

OBJECTIVES: To assess the state of pulmonary vascular mediator systems during the stepwise formation of the chronic obstructive pulmonary disease (COPD) model.
MATERIALS AND METHODS: The COPD model was induced in rats by nitrogen dioxide (NO2) inhalation for 60 days. At different stages of COPD (15, 30, and 60 days), the effect of reagents-vasodilators (β-adrenoceptor agonist isoproterenol, nitric oxide donor nitrosorbide, acetylcholine, activator of C-fibers capsaicin, corticosteroid beclometasone) on the isolated pulmonary arteries (diameter <0.5 mm) was studied. Vascular reactivity was assessed by determining isometric contraction (tension in milligrams) of arterial rings by using an electromechanical transducer.
RESULTS: All vasodilators dose-dependently decreased the vascular tone of pulmonary arteries isolated from intact rats. After 15 days of NO2 exposure, dilatation effect of low doses of vasodilators did not differ from that of intact specimens. The functional state of the adrenergic system deteriorated faster than that of the nonadrenergic noncholinergic system as reflected by the weakening of the isoproterenol relaxation effect. On prolonged NO2 exposure, pulmonary arteries responded to the impact of all vasodilators with smaller relaxation. Dose dependence of the dilatation reaction disappeared for isoproterenol, capsaicin, beclometasone, and was less expressed for nitrosorbide and acetylcholine after 60 days of exposure.
CONCLUSION: In the course of COPD model generation, the functioning of almost all neurotransmitter systems of pulmonary artery wall was negatively affected. This led to a decrease in the influence of vasodilators on pulmonary artery vascular tone and could facilitate the development of pulmonary hypertension, which is typical of COPD.

Entities:  

Year:  2020        PMID: 32203000      PMCID: PMC7089702          DOI: 10.5152/TurkThoracJ.2019.18197

Source DB:  PubMed          Journal:  Turk Thorac J        ISSN: 2148-7197


  14 in total

1.  [Broncholytic effect of prednisolon in the rats inhaled with nitrogen dioxide].

Authors:  A N Fedin; N A Kuzubova; L N Danilov; E S Lebedeva; T Iu Postnikova; A I Krivchenko
Journal:  Ross Fiziol Zh Im I M Sechenova       Date:  2010-03

Review 2.  Role of endothelin in the control of peripheral vascular tone in human hypertension.

Authors:  S Taddei; A Virdis; L Ghiadoni; I Sudano; A Magagna; A Salvetti
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

3.  Impaired NO-dependent inhibition of store- and receptor-operated calcium entry in pulmonary vascular smooth muscle after chronic hypoxia.

Authors:  Nikki L Jernigan; Brad R S Broughton; Benjimen R Walker; Thomas C Resta
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-10-21       Impact factor: 5.464

Review 4.  Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma.

Authors:  Adam Wanner; Gabor Horvath; Jorge L Brieva; Sunil D Kumar; Eliana S Mendes
Journal:  Proc Am Thorac Soc       Date:  2004

5.  Experimental modelling of chronic obstructive pulmonary disease.

Authors:  E S Lebedeva; N A Kuzubova; L N Danilov; O N Titova; I V Dvorakovskaya; M Ya Kozlova; T N Preobrazhenskaya; I S Platonova
Journal:  Bull Exp Biol Med       Date:  2012-03       Impact factor: 0.804

Review 6.  Calcium handling in vasoconstriction to stimulation of alpha 1- and alpha 2-adrenoceptors.

Authors:  P B Timmermans; A T Chiu; M J Thoolen
Journal:  Can J Physiol Pharmacol       Date:  1987-08       Impact factor: 2.273

7.  Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats.

Authors:  H Nakazawa; M Hori; H Ozaki; H Karaki
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 8.  Pulmonary hypertension in COPD: pathophysiology and therapeutic targets.

Authors:  E Zakynthinos; Z Daniil; J Papanikolaou; D Makris
Journal:  Curr Drug Targets       Date:  2011-04       Impact factor: 3.465

Review 9.  Dysfunction of pulmonary vascular endothelium in chronic obstructive pulmonary disease: basic considerations for future drug development.

Authors:  Qin Yang; Malcolm J Underwood; Michael K Y Hsin; Xiao-Cheng Liu; Guo-Wei He
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

Review 10.  Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators.

Authors:  Charles D Burger
Journal:  COPD       Date:  2009-04       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.